Explore the vast range of titles available.

An implicit Crank–Nicolson procedure can be replaced with an explicit iteration process. An explicit finite‐difference time‐domain method based on the iterated Crank–Nicolson scheme that has been widely used for solving Einstein's equations is newly developed. The formulation is presented with two iterations and its stability condition is also derived. Numerical results are found to agree well with those obtained from the traditional explicit finite‐difference time‐domain method, showing the validity of the present iterated Crank–Nicolson–finite‐difference time‐domain method.

The finite‐difference time‐domain (FDTD) method based on the iterated Crank–Nicolson (ICN) scheme is extended to a frequency‐dependent version. The Drude model is used to express a metal dispersion, which is incorporated into the iterated Crank–Nicolson formulation with the trapezoidal recursive convolution technique. The validity of the present finite‐difference time‐domain method with convolutional perfectly matched layers is discussed through the analysis of a metal‐insulator‐metal plasmonic waveguide. Numerical results obtained from a two‐iteration technique are found to agree well with those from the traditional explicit finite‐difference time‐domain method. The transmission spectra are calculated using the proposed FDTD method based on the iterated Crank‐ Nicolson scheme. The result obtained from the proposed method is in perfect agreement with that obtained from the traditional explicit FDTD method.

Various metal-insulator-metal- (MIM-) type plasmonic waveguides and gratings are investigated numerically. Three gratings are treated: one is formed by alternately stacking two kinds of MIM waveguides, another by periodic changes in the dielectric insulator materials of an MIM waveguide, and the other by a periodic variation of the air core width in an MIM waveguide. The dispersion property of each MIM waveguide of which the grating consists is analyzed using the implicit Yee-mesh-based beam-propagation method. It is shown that the third one has a relatively large effective index modulation of the guided mode with a simple grating structure, while maintaining a low propagation loss. Further examination is given to modifications of this grating structure. The transmission characteristics are examined using the frequency-dependent implicit locally one-dimensional FDTD method. We discuss how the modified grating structure affects the bandgap of the transmission characteristics.

The dispersive contour-path (DCP) finite-difference time-domain (FDTD) method is extended to the analysis of arbitrarily shaped dispersive media at terahertz frequencies. For the analysis of a grating consisting of InSb-coated dielectric cylinders, the computation time of the DCP-FDTD method is shown to be reduced to less than 20%, when compared with the traditional technique. The coupling behavior of the field to the substrate is also explained using the phase matching condition.

Ana Vukovic 1 and Martin Cryan 2 and Snjezana Tomljenovic-Hanic 3 and Jun Shibayama 4 1, George Green Institute for Electromagnetic Research, The University of Nottingham, Nottingham NG7 2RD, UK 2, Department of Electrical and Electronic Engineering, University of Bristol, Bristol BS8 1UB, UK 3, School of Physics, The University of Melbourne, Parkville, VIC 3010, Australia 4, Faculty of Science and Engineering, Hosei University, 3-7-2 Kajino-cho, Koganei, Tokyo 184-8584, Japan Received 30 November 2010; Accepted 30 November 2010 Optical waveguides and resonant cavities offer highly valuable ways of manipulating and processing light over short distances. The fifth paper presents an improved design for CMOS compatible Electro-Optic (EO) modulator that combines lithium niobate and organic polymers on a silicon substrate.

Perovskite solar cells (PSCs) are among the most promising photovoltaic technologies owing to their exceptional optoelectronic properties 1 , 2 . However, the lower efficiency, poor stability and reproducibility issues of large-area PSCs compared with laboratory-scale PSCs are notable drawbacks that hinder their commercialization 3 . Here we report a synergistic dopant-additive combination strategy using methylammonium chloride (MACl) as the dopant and a Lewis-basic ionic-liquid additive, 1,3-bis(cyanomethyl)imidazolium chloride ([Bcmim]Cl). This strategy effectively inhibits the degradation of the perovskite precursor solution (PPS), suppresses the aggregation of MACl and results in phase-homogeneous and stable perovskite films with high crystallinity and fewer defects. This approach enabled the fabrication of perovskite solar modules (PSMs) that achieved a certified efficiency of 23.30% and ultimately stabilized at 22.97% over a 27.22-cm 2 aperture area, marking the highest certified PSM performance. Furthermore, the PSMs showed long-term operational stability, maintaining 94.66% of the initial efficiency after 1,000 h under continuous one-sun illumination at room temperature. The interaction between [Bcmim]Cl and MACl was extensively studied to unravel the mechanism leading to an enhancement of device properties. Our approach holds substantial promise for bridging the benchtop-to-rooftop gap and advancing the production and commercialization of large-area perovskite photovoltaics. A synergistic dopant-additive combination strategy using methylammonium chloride as the dopant and a Lewis-basic ionic-liquid additive is shown to enable the fabrication of perovskite solar modules achieving record certified performance and long-term operational stability.

Patients with paroxysmal nocturnal hemoglobinuria who had a poor response to eculizumab therapy were found to have a genetic polymorphism in C5 that prevents binding by the antibody. Paroxysmal nocturnal hemoglobinuria (PNH) arises as a consequence of clonal expansion of hematopoietic stem cells that have acquired a somatic mutation in the gene encoding phosphatidylinositol glycan anchor biosynthesis class A ( PIGA ). 1 – 3 The resulting hematopoietic cells are deficient in glycosylphosphatidylinositol-anchored proteins, including the complement regulatory proteins CD55 and CD59; this accounts for the intravascular hemolysis that is the primary clinical manifestation of PNH. 4 – 6 PNH frequently develops in association with disorders involving bone marrow failure, particularly aplastic anemia. Thrombosis is a major cause of PNH-associated morbidity and mortality, particularly among white patients. 7 – 9 Eculizumab (Soliris, Alexion Pharmaceuticals) . . .

Polatuzumab vedotin (pola) is a CD79b‐targeted antibody‐drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open‐label, single‐arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2, rituximab 375 mg/m2 (pola + BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Primary endpoint was complete response rate (CRR) at the end of the treatment (EOT) by positron emission tomography–computed tomography (PET‐CT) using modified Lugano Response Criteria. Secondary endpoints included efficacy, safety, and pharmacokinetics. Thirty‐five patients (median age 71 [range 46‐86] years) were enrolled. Twenty‐three (66%) patients had refractory disease, and 23 (66%) had ≥2 prior lines of therapy. At a median follow‐up of 5.4 (0.7‐11.9) months, patients received a median of five treatment cycles. CRR was 34.3% (95% confidence interval [CI] 19.1‐52.2) at EOT. Overall response rate was 42.9% at EOT, and median progression‐free survival was 5.2 months (95% CI 3.6‐not evaluable). Median overall survival was not reached. No fatal adverse events (AEs) were observed. Grade 3‐4 AEs were mainly hematological: anemia (37%), neutropenia (31%), white blood cell count decreased (23%), thrombocytopenia/platelet count decreased/neutrophil count decreased (20% each), and febrile neutropenia (11%). Grade 1‐2 peripheral neuropathy (PN; sensory and/or motor) was reported in 14% of patients; there were no ≥grade 3 PN events. This study (JapicCTI‐184048) demonstrated the efficacy and safety of pola + BR in Japanese patients with R/R DLBCL who were ineligible for ASCT. We report the results of an open‐label, single‐arm study of polatuzumab vedotin 1.8 mg/kg, bendamustine 90 mg/m2, rituximab 375 mg/m2 in patients with transplant‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). A complete response rate of 34.3% at the end of the treatment and consistent safety profile with previous studies with polatuzumab vedotin were observed.